CoChat

The effects of glucagon‐like peptide‐1 on the beta cell

Vilsbøll, T. · 2009 · Diabetes, Obesity and Metabolism
Cited by 115

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Type 2 diabetes is a progressive disease characterized by insulin resistance and impaired beta‐cell function. Treatments that prevent further beta‐cell decline are therefore essential for the management of type 2 diabetes. Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone that is known to stimulate glucose‐dependent insulin secretion. Furthermore, GLP‐1 appears to have multiple positive effects on beta cells. However, GLP‐1 is rapidly degraded by dipeptidyl peptidase‐4 (DPP‐4), which limits the clinical relevance of GLP‐1 for the treatment of type 2 diabetes. Two main classes of GLP‐1‐based therapies have now been developed: DPP‐4 inhibitors and GLP‐1 receptor agonists. Liraglutide and exenatide are examples of GLP‐1 receptor agonists that have been developed to mimic the insulinotropic characteristics of endogenous GLP‐1. Both have demonstrated improved beta‐cell function in patients with type 2 diabetes, as assessed by homoeostasis model assessment‐B analysis and proinsulin : insulin ratio. Additionally, liraglutide and exenatide are able to enhance first‐ and second‐phase insulin secretion and are able to restore beta‐cell sensitivity to glucose. Preclinical studies have shown that both liraglutide and exenatide treatment can increase beta‐cell mass, stimulate beta‐cell proliferation, increase beta‐cell neogenesis and inhibit beta‐cell apoptosis. Clinical studies are needed to confirm these findings in humans. Replication of these data in humans could have important clinical implications for the treatment of type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2009.01073.x

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 115

Metadata

Authors
Vilsbøll, T.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2009-10-29
Volume
11
Issue
s3
Pages
11-18
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2038335142
Cited by
115
References
26
FWCI
7.18
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effects of glucagon‐like peptide‐1 on the beta cell. https://app.cochat.ai/papers/10.1111/j.1463-1326.2009.01073.x
The paper
Vilsbøll, T. (2009). The effects of glucagon‐like peptide‐1 on the beta cell. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2009.01073.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.